论文部分内容阅读
目的探讨复方倍他米松经鼓室内给药治疗突发性耳聋(SD)的临床疗效。方法选取2013年4月—2016年4月南京大学医学院附属金陵医院收治的SD患者60例,根据给药方式不同将患者分为鼓室组和常规组,各30例。两组患者均给予SD基础治疗,在此基础上,鼓室组接受复方倍他米松经鼓室内给药治疗,常规组采取肌肉注射复方倍他米松治疗。比较两组患者治疗前后听阈情况、临床疗效及不良反应发生率。结果两组患者治疗前听阈均值比较,差异无统计学意义(P>0.05);治疗后鼓室组听阈均值低于常规组,差异有统计学意义(P<0.05),两组患者听阈均值低于治疗前,差异有统计学意义(P<0.05)。鼓室组总有效率高于常规组,不良反应发生率低于常规组,差异有统计学意义(P<0.05)。结论鼓室注射复方倍他米松治疗SD的疗效确切、不良反应少,是一种安全有效的治疗方案。
Objective To investigate the clinical efficacy of compound betamethasone in the treatment of sudden deafness (SD) by intratracheal administration. Methods From April 2013 to April 2016, 60 SD patients admitted to Jinling Hospital Affiliated to Nanjing University Medical College were divided into tympanic group and conventional group according to different administration methods, 30 cases in each group. Two groups of patients were given SD basic treatment, on this basis, the tympanic group received compound betamethasone administered via the intratympanic tract, the conventional group to take intramuscular injection of compound betamethasone treatment. The hearing threshold, clinical efficacy and incidence of adverse reactions were compared between the two groups before and after treatment. Results There was no significant difference in mean hearing threshold between the two groups before treatment (P> 0.05). The average hearing threshold of the tympanic group was lower than that of the conventional group after treatment (P <0.05) Before treatment, the difference was statistically significant (P <0.05). The total effective rate in the tympanic group was higher than that in the conventional group, and the incidence of adverse reactions was lower than that in the conventional group (P <0.05). Conclusion The tympanic injection of compound betamethasone in the treatment of SD is effective and has few adverse reactions. It is a safe and effective treatment plan.